PCMRI - an MRI/TRUS System for the Evaluation of the Prostate

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by TopSpin Medical.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
TopSpin Medical
ClinicalTrials.gov Identifier:
NCT00542100
First received: October 7, 2007
Last updated: October 9, 2007
Last verified: October 2007
  Purpose

The aim of the clinical study is to evaluate the convenience and efficacy of the PCMRI in the assessment of the prostate in humans.

The study cohort will include 50 patients and is designed to be non-comparative to other diagnostic methods.


Condition Intervention
Prostate Cancer
Device: PCMRI

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Resource links provided by NLM:


Further study details as provided by TopSpin Medical:

Primary Outcome Measures:
  • Efficacy of the PCMRI system in PC detection [ Time Frame: one year ]
  • Safety of the PCMRI system in PC detection [ Time Frame: one year ]

Secondary Outcome Measures:
  • Patient comfort [ Time Frame: one year ]
  • Compliance [ Time Frame: one year ]
  • Ease of use [ Time Frame: one year ]
  • Length of the test procedure [ Time Frame: one year ]

Estimated Enrollment: 50
Study Start Date: November 2007
Estimated Study Completion Date: November 2008
Arms Assigned Interventions
Experimental: 1 Device: PCMRI
Experimental: 2 Device: PCMRI

Detailed Description:

Prostate cancer (PC) is the most common male malignancy in the western world. In the U.S. there are approximately 230,000 new diagnoses annually. Each year, 40,000 men with established disease die from PC.

Early detection is possible using prostate specific antigen (PSA) and/or DRE, followed by biopsy if PC is suspected. Biopsy is generally carried out under transrectal ultrasound (TRUS) guidance through the rectum wall. Typically, 6-13 samples from different areas of the prostate are taken in order to cover the entire gland area. Since TRUS cannot accurately detect PC, prostate biopsies, to date, are in fact random biopsies. Furthermore, PSA may be elevated, in patients without PC, leading to as many as 75% of patients undergoing unnecessary TRUS guided biopsy [1,2].

The need for accurate preoperative evaluation of PC, as well as early detection of the tumor has lead to numerous applications of Magnetic Resonance Imaging (MRI) of the prostate.1 The sensitivity and specificity of whole body MRI with pelvic phased-array coils is as low as ~70%. Improved sensitivity is obtained using an endorectal coil where efficacies of ~85% are reported due to the improved signal to noise ratio (SNR) of such coils.2

One of the major limitations of conventional MRI scanners is their cost and limited availability. A portable, hand-held MR scanner capable of detecting PC is thus, of interest. TopSpin has developed a novel MRI based system for prostate imaging in Urology. The primary use of the prostate MRI probe will be diagnosis, staging and guidance of minimally invasive therapy for PC.

The system consists of a miniaturized transrectal MRI probe, incorporating all magnetic field sources and coils. The MRI probe is integrated with and used in conjunction with a TRUS system. The TRUS probe provides prostate gross anatomy and allows the Urologist to select the cross-section(s) of interest within the prostate. The MRI probe provides MRI images of the selected cross-section(s) with improved tissue characterization that enable localizing tumors within the prostate. Fusion of both images has promise of significantly improving the ability to direct biopsies to regions of a much higher likelihood for being malignant. In addition, the system is capable of guiding local treatment such as Cryotherapy or Brachytherapy.

The integrated MRI-TRUS system resembles a state-of-the-art, high-end ultrasound system. The MR-TRUS probe is connected to a cart based console, which houses the electronics hardware required for both MR and ultrasound activation. An investigational device will be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). It will be used in accordance with the approved protocol. Procedures that assure the quality of every aspect of the trial will be implemented.

  Eligibility

Ages Eligible for Study:   25 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria for trial group:

  • Age between 45 and 80 years old.
  • Presumably Stage 2 and higher prostate carcinoma as determined by the PI.
  • At least 6 weeks after the last biopsy session.
  • Prior to any PC treatment. for control group:
  • Age between 25 and 35 years old.
  • No family history of PC.
  • No lower urinary tract symptoms. Exclusion criteria for both groups:
  • History of hemorrhoids.
  • History of prostetitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00542100

Sponsors and Collaborators
TopSpin Medical
Investigators
Principal Investigator: Shmuel Cytron, MD. Barzilai Medical Center, Ashkelon, Israel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00542100     History of Changes
Other Study ID Numbers: PCL-2-001
Study First Received: October 7, 2007
Last Updated: October 9, 2007
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 21, 2014